
- 1. The clinical features of adult Still's disease resemble the systemic form of JRA
  - Seronegative chronic polyarthritis associated with a systemic inflammatory illness
  - b. Initially described in 1897 by George F. Still (pathologist)
  - c. Subsequently detailed in adults in 1971 by Eric Bywaters
- 2. Epidemiology
  - a. Rare
  - b. Affects both genders equally
  - c. Exists worldwide
  - d. Majority present at age 16–35 years
    - i. 75% before age 35
- 3. Pathogenesis
  - a. Etiology unknown
  - b. Principal hypothesis implicates a virus or other infectious agent
  - c. Linkage to HLA antigens inconclusive
  - d. Immune complexes may play a pathogenic role (not confirmed)
  - e. NO association with pregnancy and use of hormones
  - f. Stress may play a role as inducer (not confirmed)
  - g. Circadian release of proinflammatory cytokines
    - i. Accounts for many clinical features
    - ii. IL-6
    - iii. IL-18
      - 1. Elevated
      - 2. Stimulates ferritin synthesis in monocytes/macrophages
- 4. Clinical Findings
  - a. Preceded by a prolonged course of nonspecific signs and symptoms
  - b. A prodromal sore throat occurs days to weeks before other symptoms
    - i. Occurs in 70% (50–92%)
  - c. The most striking manifestations
    - i. Severe arthralgia (98–100%) and myalgia (84–98%)
    - ii. Malaise

- iii. Weight loss (19–76%)
- iv. Fever (83–100%)
- d. Less common clinical manifestations
  - i. Lymphadenopathy (48–74%)
  - ii. Splenomegaly (45–55%)
  - iii. Pleuritis (23–53%)
  - iv. Abdominal pain (9–48%)
  - v. Hepatomegaly (29-44%)
  - vi. Pericarditis (24–37%)
  - vii. Pneumonitis (9–31%)
- e. Unusual manifestation (numerous)
  - i. Alopecia
  - ii. Sjogren's
  - iii. Subcutaneous nodules
  - iv. Necrotizing lymphadenitis
  - v. Acute liver failure
  - vi. Pulmonary fibrosis
  - vii. Cardiac tamponade
  - viii. Aseptic meningitis
    - ix. Peripheral neuropathy
    - x. Proteinuria
    - xi. Microscopic hematuria
  - xii. Amyloidosis
  - xiii. Hemolytic anemia
  - xiv. DIC
  - xv. TTP
  - xvi. Orbital pseudotumor
  - xvii. Cataracts
- xviii. Sensorineural hearing loss
  - xix. Hemophagocytic syndrome
- f. Patients appear severely ill
  - i. Often receive numerous courses of antibiotics
  - ii. Presumed septic with negative cultures
- g. Fever
  - i. Initial symptom
  - ii. Usually sudden onset high and spiking
  - iii. Spikes once daily (rarely twice daily)
    - 1. Usually early morning and/or late afternoon/evening
    - 2. Quotidian or diquotidian pattern
  - iv. Lasts 2-4 h
  - v. Temperature elevation marked
    - 1. 66% with fever>40°C
  - vi. Returns to normal in 80% of untreated patients
    - 1. Can return below normal



**Fig. 16.1** Fever pattern in adult-onset Still's disease (Reproduced with permission from Rheumatoid arthritis, juvenile rheumatoid arthritis, and related conditions. *Atlas of Rheumatology*. ImagesMD; 2002-03-07)

- vii. Very ill when febrile
  - 1. Feels well with normal body temp
- viii. Pattern contrasts with that seen with infection
  - 1. Baseline elevation in body temperature
  - 2. Episodic fever spikes
  - ix. Patients evaluated for FUO
    - 1. 5% eventually diagnosed with Still's
- h. Arthritis (88–84%)
  - i. Initially affects only a few joints
  - ii. Evolves to polyarticular disease
  - iii. Most commonly affected joints
    - 1. Knee (84%)
    - 2. Wrist (74%)
    - 3. Ankle, shoulder, elbow, and PIP joints (50%)
    - 4. MCP (33%)
    - 5. DIP (20%)
  - iv. Other joints affected
    - 1. MTPs
    - 2. Hips
    - 3. Tempromandibular joint (TMJ)
  - v. Neck pain (50%)
  - vi. Arthrocentesis yields
    - 1. Class II inflammatory synovial fluid
    - 2. Neutrophil predominance
  - vii. Destructive arthritis (20–25%)

**Fig. 16.2** Wrist involvement in adult-onset Still's disease (Reproduced with permission Rheumatoid arthritis, juvenile rheumatoid arthritis, and related conditions. *Atlas of Rheumatology*. ImagesMD; 2005-01-18)



**Fig. 16.3** Rash in adult-onset Still's disease (Reproduced with permission from Rheumatoid arthritis, juvenile rheumatoid arthritis, and related conditions. *Atlas of Rheumatology.* ImagesMD; 2002-03-07)



## i. Still's rash

- i. Present in more than 85% of patients
- ii. Almost pathognomonic
- iii. Salmon pink
- iv. Macular or maculopapular
- v. Frequently evanescent
- vi. Often occurs with the evening fever spike
  - 1. Evening rounds may detect this near-diagnostic finding
- vii. More common on the trunk and proximal extremities
- viii. Precipitated by
  - 1. Mechanical irritation
    - a. Clothing
    - b. Rubbing
    - c. Koebner's phenomenon (up to 40%)

- 2. Heat
  - a. Hot bath
  - b. Applying a hot towel
- ix. May be mildly pruritic
- x. Skin biopsies and immunofluorescent studies
  - 1. Neurivascular mononuclear cell infiltrate
  - 2. Nondiagnostic
- 5. Laboratory Findings
  - a. No diagnostic tests
  - b. Serum ferritin
    - i. An acute-phase reactant that reflects inflammation
    - ii. An extremely elevated level suggest the diagnosis
    - iii. A value of ≥1,000 mg/dl in the proper clinical setting
      - 1. Confirmatory
      - 2. Especially associated with a low glycosylated ferritin
    - iv. Values >4,000 mg/dl seen in <50%
    - v. Reason for such elevations unknown
  - c. CRP
    - i. Frequently greater than 10 times upper limit of normal
  - d. ESR
    - i. Universally elevated >50 (96–100%)
  - e. Leukocytosis
    - i. Range 12–40,000/mm<sup>3</sup> present in 90% (71–97%)
    - ii. 80% have WBC count > 15,000/mm<sup>3</sup>
    - iii. Neutrophils  $\ge 80\%$  (55–88%)
  - f. LFT
    - i. Elevated in up to three-quarters of patients (35–85%)
  - g. Anemia
    - i. Common (59–92%)
    - ii. Sometimes profound
  - h. Thrombocytosis (52–62%)
  - i. Hypoalbuminemia (44–88%)
  - j. RF and ANA
    - i. Generally negative or low titer
  - k. Synovial and serosal fluids
    - i. Inflammatory
    - ii. Predominance of neutrophils
- 6. Radiographic Findings
  - a. Early
    - i. Soft-tissue swelling
    - ii. Effusions
    - iii. Periarticular osteoporosis (occasionally)

**Fig. 16.4** Radiographic changes in adult-onset Still's disease include periarticular osteopenia and loss of joint space (Reproduced with permission from Rheumatoid arthritis, juvenile rheumatoid arthritis, and related conditions. *Atlas of Rheumatology*. ImagesMD; 2002-03-07)



## b. Late

- i. Joint erosions
- ii. Fusions
  - 1. Carpal bones (50%)
  - 2. Tarsal bones (20%)
  - 3. Cervical spine (10%)
- c. Characteristic radiographic findings
  - i. Typically found in the wrist
  - ii. Nonerosive narrowing of carpometacarpal and intercarpal joints
  - iii. Progresses to bony ankylosis

## 7. Diagnosis

- a. Diagnosis one of exclusion
  - i. With the proper clinical and laboratory abnormalities
  - ii. With the absence of another explanation (infection or malignancy)
- b. Criteria of Cush (practical guide)
  - i. Diagnosis requires the presence of all of the following
    - 1. Fever  $> 39^{\circ}$ C (102.2°F)
    - 2. Arthralgia or arthritis
    - 3. RF < 1:80
    - 4. ANA < 1:100

- ii. In addition, any two of the following
  - 1. WBC count  $\geq$  15.000 cells/mm<sup>3</sup>
  - 2. Still's rash
  - 3. Pleuritis or pericarditis
  - 4. Hepatomegaly or splenomegaly or generalized lymphadenopathy
- c. Most do not present with the full-blown syndrome
- d. Typical presentation for adult Still's disease
  - i. High, daily fever spikes
  - ii. Severe myalgia, arthralgia, and arthritis
  - iii. Still's rash
  - iv. Leukocytosis
- e. Markedly elevated serum ferritin highly suggestive
- 8. Differential Diagnosis
  - a. Granulomatous disorders
    - i. Sarcoidosis
    - ii. Idiopathic granulomatosis hepatitis
    - iii. Crohn's disease
  - b. Vasculitis
    - i. Serum sickness
    - ii. PAN
    - iii. Wegener's
    - iv. TTP
    - v. Takayasu's
  - c. Infection
    - i. Viral
      - 1. Hepatitis B
      - 2. Rubella
      - 3. Parvovirus
      - 4. Coxsackie
      - 5. EBV
      - 6. CMV
      - 7. HIV
    - ii. Subacute bacterial endocarditis
    - iii. Chronic meningococcemia
    - iv. Gonococcemia
    - v. TB
    - vi. Lyme
    - vii. Syphilis
    - viii. Rheumatic fever
  - d. Malignancy
    - i. Leukemia
    - ii. Lymphoma
    - iii. Angioblastic lymphadenopathy

- e. Connective tissue disease
  - i. SLE
  - ii. Mixed connective tissue disease
- 9. Disease Course and Outcome
  - a. Median time to achieve clinical and laboratory remission
    - i. 10 months while receiving therapy
    - ii. 32 months requiring no therapy
  - b. Can remit years after onset
  - c. Course generally follows one of three patterns (one-third of patients each)
    - i. Self-limited disease
      - 1. Remission within 6–9 months
      - 2. One-fifth to one-third
    - ii. Intermittent flares
      - 1. One recurrence
        - a. Two-thirds
        - b. 10–36 months from the original illness
      - 2. Multiple flares
        - a. Up to ten flares reported
        - b. Intervals of 3–48 months
        - c. Recurrent episodes generally milder than the original
        - d. Respond to lower doses of meds
        - e. Timing of relapse unpredictable
    - iii. Chronic Still's disease
      - 1. Chronic arthritis is the principle problem
      - 2. Severe involvement of the knees and hips
        - a. Require total joint replacement
      - 3. Most common in the hip
  - d. Markers of chronic disease or poor prognosis
    - i. Presence of polyarthritis (four or more joints involved)
    - ii. Root joint involvement (shoulders or hips)
    - iii. A childhood episode
      - 1. Occurs in about one of six patients
    - iv. More than 2 years of therapy with systemic corticosteroids
  - e. A controlled study of patients 10 years after the diagnosis of Still's
    - i. Significant higher levels of pain, physical disability, and psychologic disability than unaffected siblings
    - ii. Levels of pain and disability lower than other chronic rheumatic disease
    - iii. No difference in Still's patients and controls in overcoming handicaps
      - 1. Educational attainment
      - 2. Occupational prestige
      - 3. Social functioning
      - 4. Family income
  - f. 5 year survival rate 90–95%
    - i. Similar to the survival rate for lupus
    - ii. Vast majority lead remarkably full lives after disease onset

- g. Premature death may be slightly increased
- h. Causes of mortality
  - i. Hepatic failure
  - ii. DIC
  - iii. Amyloidosis
  - iv. Sepsis
  - v. Acute respiratory distress syndrome (ARDS)
  - vi. Heart failure
  - vii. Carcinoma of the lung
  - viii. Status epilepticus
- 10. Acute Treatment
  - a. NSAIDs
    - i. About one-fourth respond (20–40%)
    - ii. A commonly used regimen
      - 1. High dose enteric-coated aspirin
      - 2. Achieve a serum salicylate level of 15–25 mg/dl
      - 3. Sometimes combined with indomethacin (150 mg/day)
    - iii. Side effects
      - 1. Hepatotoxicity
        - a. Elevated LFTs usually return to normal
        - b. Despite continued NSAID therapy
      - 2. Increased risk of DIC
  - b. Systemic corticosteroids
    - i. Patients who fail to respond to NSAIDs
    - ii. For severe disease
      - 1. Pericardial tamponade
      - 2. Myocarditis
      - 3. Severe pneumonitis
      - 4. DIC
      - 5. Rising LFTs during NSAID treatment
    - iii. Prednisone in a dose of 0.5–1.0 mg/kg/day
    - iv. About one-third require at least 60 mg of prednisone daily
    - v. Relapses occur during tapering
      - 1. Add one of the slow-acting antirheumatic drugs
        - a. Methotrexate
    - vi. IV pulse methylprednisolone used for life-threatening disease
- 11. Chronic Treatment
  - a. Medications used to treat arthritis (the most common cause of chronicity)
    - i. IM gold
    - ii. Hydroxychloroquine
      - 1. Mild chronic systemic disease may respond as well
        - a. Fatigue
        - b. Fever
        - c. Rash
        - d. Serositis

- iii. Sulfasalazine
  - 1. Increased toxicity may occur
- iv. Penicillamine
- v. Methotrexate
  - 1. Low doses (similar to those used in RA)
  - 2. Used in both chronic arthritis and chronic systemic disease
- b. Immunosuppressive agents
  - i. Used in resistant cases
  - ii. Azathioprine
  - iii. Cyclophosphamide
  - iv. Cyclosporine
  - v. IVIG (controversial)
  - vi. Mycophenolate mofetil
  - vii. Leflunomide
- c. Biologics
  - i. TNF-α elevated in Still's disease
  - ii. Etanercept and infliximab beneficial
    - 1. Especially articular manifestations
  - iii. Anakinra
    - 1. Successful in refractory disease
- d. Therapy after a decade of disease
  - i. About one-half of patients will require second-line agents
  - ii. One-third will require low-dose corticosteroids
- e. Multidisciplinary approach
  - i. Physiotherapists
  - ii. Occupational therapists
  - iii. Psychologists
  - iv. Arthritis support groups